Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age

Abstract

Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana.Objectives: The aim of the present review is to describe the main advances in the development of the experimental and clinical use of cannabidiol CBD in neuropsychiatry.Methods: A non-systematic search was performed for studies dealing with therapeutic applications of CBD, especially performed by Brazilian researchers.Results: CBD was shown to have anxiolytic, antipsychotic and neuroprotective properties. In addition, basic and clinical investigations on the effects of CBD have been carried out in the context of many other health conditions, including its potential use in epilepsy, substance abuse and dependence, schizophrenia, social phobia, post-traumatic stress, depression, bipolar disorder, sleep disorders, and Parkinson.Discussion: CBD is an useful and promising molecule that may help patients with a number of clinical conditions. Controlled clinical trials with different neuropsychiatric populations that are currently under investigation should bring important answers in the near future and support the translation of research findings to clinical settings.

Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?

“…The antiepileptic, anxiolytic, antipsychotic, and neuroprotective effects induced by CBD lead to suggest that it is an excellent candidate to control drug‐resistant epilepsy and comorbid disorders . This notion is supported by results obtained from experimental models of temporal lobe epilepsy, a neurological disorder with a high prevalence of drug resistance and comorbid psychiatric symptoms .…”

Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals

“…CBD is the most well‐known of the non‐euphoric phytocannabinoids contained in the marijuana or hemp plant, Cannabis sativa . It was first isolated in 1940 by Adams and co‐workers, but its structure and stereochemistry were determined in 1963 by Mechoulam and Shvo (Crippa, Guimarães, Campos, & Zuardi, ; Izzo, Borrelli, Capasso, di Marzo, & Mechoulam, ). In contrast to Δ 9 ‐tetrahydrocannabinol (THC), which has euphoric properties due to activation of brain cannabinoid CB 1 receptors, CBD has very low affinity for both CB 1 and CB 2 receptors, has no known abuse potential and exerts multiple pharmacological actions (e.g.…”

“…Synthetically produced AX consists only of the trans isomer and has been reported to contain trace amounts of residual solvents and chemical reagents (Edwards et al 2016 (Crippa, Guimarães, Campos, & Zuardi, 2018;Izzo, Borrelli, Capasso, di Marzo, & Mechoulam, 2009). In contrast to Δ 9 -tetrahydrocannabinol (THC), which has euphoric properties due to activation of brain cannabinoid CB 1 receptors, CBD has very low affinity for both CB 1 and CB 2 receptors, has no known abuse potential and exerts multiple pharmacological actions (e. In addition to the FDA-approved medicine, CBD products are sold in "smoke" shops, convenience stores and over the Internet (White, 2019).…”

Lung alveolar tissue destruction and protein citrullination in diesel exhaust‐exposed mouse lungs

“…Phytocannabinoids, like cannabidiol (CBD), have been widely studied as candidate therapeutics . CBD is an abundant non‐psychoactive component of industrial hemp ( Cannabis sativa ) plant material with anti‐inflammatory and antioxidant effects .…”

“…38 Phytocannabinoids, like cannabidiol (CBD), have been widely studied as candidate therapeutics. 39,40 CBD is an abundant non-psychoactive component of industrial hemp (Cannabis sativa) plant material with anti-inflammatory and antioxidant effects. 41,42 It can attenuate effects of certain toxins, 43 ameliorate oxidative stress, 44 is already being tested in several clinical trials 45,46 and used clinically, that is for the treatment of certain forms of epilepsy.…”